← Eichor
Study identifier: NCT05767216 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

Condition: Down Syndrome  ·  Sponsor: Institut Jerome Lejeune

PhaseNA
Planned participants5
Who can joinMale, 4 Years to 11 Years
Healthy volunteersYes

About this study

Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population. Sharing the same genetic patrimony, except for an additional chromosome 21 for one of them, any gene-expression difference between them could be attributed only to the supernumerary chromosome 21 and not to polymorphic variability in the rest of the genome. The setting up of a prospective longitudinal study will offer the major advantage of allowing genetic and epigenetic comparisons between them and to obtain important information on the impact of the environment in which they live and grow up.

This description comes directly from the study's public registry record.

Talk to the study team

Sophie Durand  ·  0033156586300  ·  sophie.durand@institutlejeune.org

Always discuss trial participation with your own doctor first.

Locations (1)

Institut Jérôme LejeuneParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05767216